Trials / Recruiting
RecruitingNCT06840717
Association Between Genetic Polymorphisms and Type 2 Asthma in Children
Association Between Cytokines Gene Single Nucleotide Polymorphisms and Type 2 Inflammatory Asthma in Children
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Guangzhou Institute of Respiratory Disease · Academic / Other
- Sex
- All
- Age
- 3 Years – 14 Years
- Healthy volunteers
- Accepted
Summary
To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.
Detailed description
Type of study: This was a prospective, randomized case-control design.To investigate the role of genetic single nucleotide polymorphisms (SNPs) in children with type 2 asthma, and the effects of SNPs on type 2 inflammatory markers and pulmonary function indicators. Methods: Children with asthma who were treated at our pediatric respiratory specialty clinic and who met the criteria for type 2 inflammation were included in the case group (Type 2 inflammation was considered to be present if any of the following conditions were present: Fraction of exhaled nitric oxide(FeNO)≥20ppb;Blood eosinophilcount≥350/ul;Percentage of sputum eosinophils\>3%; Asthma is caused by inhaled allergens.). The control group is healthy children who underwent physical examination. To compare the differences of single nucleotide polymorphisms (SNPs) between children with type 2 asthma and healthy children, and to explore the risk factors of type 2 asthma. The differences of indicators between different genotypes were compared, including type 2 inflammation indicators (including Fraction of exhaled nitric oxide(FeNO)、Blood eosinophil count、Percentage of sputum eosinophils and Serum total immunoglobulin E) and pulmonary function indicators(Forced expiratory volume in one second(FEV1)、Forced vital capacity(FVC)、Ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC) and Peak expiratory flow(PEF)).
Conditions
Timeline
- Start date
- 2024-01-30
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
- First posted
- 2025-02-21
- Last updated
- 2025-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06840717. Inclusion in this directory is not an endorsement.